CCFM1163 alleviates cathartic colon by activating the BDNF-TrkB-PLC/IP pathway to reconstruct the intestinal nerve and barrier.

: Cathartic colon (CC) is a type of slow-transit constipation caused by a patient's long-term use of irritating laxatives. Probiotics play a crucial role in managing constipation. : This study aims to identify probiotics that can alleviate CC and explore their specific mechanisms of action. : The CC-model was constructed using senna leaf extract. was applied to the mice for intervention. Relevant marker changes were then examined using ELISA and RT-qPCR. Furthermore, 16S rDNA sequencing was utilized for functional prediction of intestinal microorganisms, while GC-MS analysis was performed to determine the content of short-chain fatty acids (SCFAs) in feces. : Senna damages the intestinal nerve and the intestinal barrier while inducing CC. In contrast, CCFM1163 may enhance the brain-derived neurotrophic factor (BDNF) expression in the colon by altering the intestinal microbiota composition (, increasing and , and decreasing ) and by elevating SCFA levels (, acetic and isobutyric acid). Subsequently, elevated BDNF expression activates the BDNF-tyrosine kinase receptor B-phospholipase C/inositol trisphosphate (BDNF-TrkB-PLC/IP) pathway, which upregulates the gene expression of , , and ; repairs the enteric nervous system-interstitial cells of Cajal-smooth muscle cells (ENS-ICC-SMC) network; upregulates the gene expression of and ; improves intestinal permeability in CC mice; and modulates the immune response by upregulating , downregulating , and upregulating , ultimately alleviating CC. : CCFM1163 was identified as a probiotic that can promote BDNF expression in the colon, activate the BDNF-TrkB-PLC/IP signaling pathway, and effectively alleviate CC.